Completed PHASE3 INTERVENTIONAL NCT00240708

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

A Parallel-Group Comparative Open-Label Study of Long-Acting Injectible Risperidone Versus Risperidone Tablets in Patients With Schizophrenia.

Sponsor: Janssen Pharmaceutical K.K.

Conditions Schizophrenia

Interventions risperidone

Updated 5 times since 2017 Last updated: May 16, 2011 Started: Jun 30, 2004 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Schizophrenia and is currently completed. Janssen Pharmaceutical K.K. leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.